Current research suggests that the gut microbiome may affect the efficacy of anti-PD-1/L1 and anti-CTLA-4 therapies.633 Besides the gut microbiome, the characteristics of the tumor microbiome can significantly influence responses to immune therapies. The gene discussed is CTLA4; the disease is neoplasm.